BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Skyhawk’s SKY-0515 Shows 62% Reduction in Mutant Huntingtin at Day 84 in Huntington’s Disease Trial

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional finding...

September 18, 2025 | News

Contrast-Enhanced Ultrasound Shows Promise for Early Pancreatic Cancer Detection

A new study shows that contrast enhanced ultrasound (CEUS) techniques offer an encouraging option for noninvasively detecting pancreatic cancer in its earl...

September 11, 2025 | Report

Siemens Healthineers–YouGov Survey Reveals Fragmented Cancer Care Pathway in Southeast Asia, Underscoring Need for Integrated Solutions

YouGov survey finds strong belief in value of early detection (78%) but low screening uptake (26%) 80% of respondents aware post-treatment care exists...

September 10, 2025 | Report

The State of Biotech and Life Science Jobs in Asia Pacific – 2025

In 2025, Asia-Pacific has emerged as the fastest-growing hub for biotech and life sciences employment, fuelled by a powerful combination of government supp...

September 09, 2025 | Report

AstraZeneca’s FLAURA2 Trial Confirms TAGRISSO Plus Chemotherapy Extends Survival in EGFR-Mutated Lung Cancer

FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line s...

September 08, 2025 | News

Roche’s Vabysmo Demonstrates Strong One-Year Results in Asian Patients with Polypoidal Choroidal Vasculopathy

One-year SALWEEN results demonstrate robust efficacy, extended durability and consistent safety in patients with polypoidal choroidal vasculopathy (PCV),...

September 08, 2025 | News

South Korea’s AMI Pharm Reports Phase 2 Success of ‘AYP-101,’ a Potential New Leader in Nonsurgical Fat Reduction

AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, H...

September 02, 2025 | News

Daiichi Sankyo Europe Initiates Development of Oral Triple Combination Tablets to Enhance LDL-C Management

Daiichi Sankyo Europe announced the initiation of the development of new oral triple combination tablets in Europe containing bempedoic acid, ezetimibe, an...

September 02, 2025 | News

Wegovy® Demonstrates Superior Cardiovascular Benefit Over Tirzepatide in Real-World Study

Compared with tirzepatide, Wegovy® (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart atta...

September 01, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Sanofi and AstraZeneca’s Beyfortus Receives HSA Approval to Prevent RSV in Infants

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety ...

August 20, 2025 | Regulatory

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape

Invisible chemical impurities in medicines can pose very visible risks to patient safety and pharmaceutical reputations. In recent years, a quiet c...

August 19, 2025 | Analysis

China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus

The first seven months of 2025 saw robust dealmaking in China’s biopharma and healthcare sector, even as global headwinds tempered some activity. Chi...

August 15, 2025 | Report

Stay Connected